GRAIL (NASDAQ:GRAL) reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build international distribution partnerships. GRAIL reported a net loss of $110.2 million for the second quarter, a 3% decrease from the second quarter of 2025. Freidin said the Samsung investment provides financial flexibility as GRAIL pursues regulatory approval and reimbursement for Galleri in the U.S. Ofman said the company believes an FDA approval could prompt more substantive discussions with payers and employers. Ofman said GRAIL expects a potential FDA approval to distinguish Galleri from tests that have not yet established their risk-benefit profile in intended-use populations.